Cargando…
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients wh...
Autores principales: | Terpos, Evangelos, Kanellias, Nikolaos, Christoulas, Dimitrios, Kastritis, Efstathios, Dimopoulos, Meletios A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656921/ https://www.ncbi.nlm.nih.gov/pubmed/23690693 http://dx.doi.org/10.2147/OTT.S34498 |
Ejemplares similares
-
Pomalidomide- and dexamethasone-based regimens in the treatment of
refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022) -
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020) -
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018) -
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021) -
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)